Bayer's KERENDIA Achieves Primary Endpoint in Phase III Trial for Type 1 Diabetes and Chronic Kidney Disease
I'm PortAI, I can summarize articles.
Bayer AG announced that its KERENDIA® (finerenone) achieved a significant reduction in urine albumin-to-creatinine ratio (UACR) by 25% in a Phase III trial for adults with type 1 diabetes and chronic kidney disease. The results were presented at the ASN Kidney Week 2025, and Bayer plans to submit a supplemental New Drug Application to the U.S. FDA in 2026 based on these findings. Additionally, data from the Phase II CONFIDENCE trial will also be presented at the event.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments